Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 6th January 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer launches new purification technology for Ingelvac CircoFLEX®
Drug firm Boehringer Ingelheim has announced new purification technology for Ingelvac CircoFLEX®.
Vaccine to be launched in all EU countries in January 2020

Pharmaceutical firm Boehringer Ingelheim has announced a new and proprietary purification process for its swine vaccine, Ingelvac CircoFLEX®.

Ingelvac CircoFLEX® was the first PCV2 (porcine circovirus type 2) that could be mixed with an M hyo vaccine to address two critical swine pathogens in a single dose. Considered to be the most revolutionary PCV2 vaccines on the market, it provides effective control of circovirus-associated disease in pigs aged three weeks and older.

The new diafiltration process, named DiaTEC, removes residual cell media components from the virus-like particles (VLPs) to obtain highly immunogenic and non-virucidal vaccine.

A press release reads: “With DiaTEC, a new and proprietary diafiltration technology, Ingelvac CircoFLEX® becomes the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm.”

Eva Joras, global brand manager at Boehringer Ingelheim, said: “I am really proud that we continuously invest in our research and development to further improve our leading products to address our customers’ needs.”

Ingelvac CircoFLEX®, manufactured with the new technology, will be launched in several different packaging sizes in all EU countries in January 2020. 

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk